ArticlePediatric surgery international2026
Intravesical botox as an effective therapy for giggle incontinence in children.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGiggle incontinence is a bladder storage disorder characterized by uncontrolled voiding during or immediately after laughter. Many children are refractory to available therapies or experience considerable side-effects. This study aimed to determine the efficacy of intravesical Botox injections in the management of giggle incontinence.
methodsA retrospective review of all children who received 200iU intravesical botulinum toxin-A for giggle incontinence over twelve years was performed. All children experienced complete bladder emptying during or immediately after laughter as their primary complaint, with or without a related voiding disorder. Outcomes were characterised as: “no response” (0–49% reduction), “partial response” (50–99% reduction), or “complete response” (100% reduction).
resultsA total 34 procedures (range: 1–5) in 17 children were included. Median age at first treatment was 11 years (range: 6-17y). Complete response occurred in 65% of patients and partial response in 18%. Of those who experienced complete response, 55% (6/11) had no relapse of symptoms with a median duration of follow-up of 5 years (IQR 3.5-6.5y).
conclusionGiggle incontinence is a rare but significant condition with marked impact on quality of life. This is the first study describing the use of intravesical Botox injection in this population, demonstrating safety and efficacy with a sustained response to treatment in many patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.